Published in N Engl J Med on February 02, 2006
Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol (2009) 3.57
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol (2009) 1.78
Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Oncotarget (2012) 1.69
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol (2010) 1.63
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer (2007) 1.55
EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch (2010) 1.45
Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One (2009) 1.45
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol (2009) 1.44
Mutation detection by real-time PCR: a simple, robust and highly selective method. PLoS One (2009) 1.29
Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol (2014) 1.28
Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. PLoS One (2011) 1.21
Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Mol Cancer (2009) 1.17
Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A (2012) 1.17
KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues. Int J Mol Sci (2011) 1.17
Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. Breast Cancer Res (2011) 1.14
A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. PLoS One (2012) 1.05
Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. BMC Cancer (2007) 1.04
Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer (2009) 1.03
Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer (2007) 1.03
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations. Sci Rep (2014) 1.01
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. Hum Mutat (2009) 0.97
Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. PLoS One (2012) 0.96
Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res (2011) 0.96
[EGFR mutation analysis in non-small-cell lung cancer : Experience from routine diagnostics]. Pathologe (2009) 0.93
EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer. Curr Oncol (2012) 0.93
Whole genome sequencing for lung cancer. J Thorac Dis (2012) 0.91
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br J Cancer (2008) 0.90
Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers. PLoS One (2015) 0.90
Detection of EGFR gene mutations in non-small cell lung cancer: lessons from a single-institution routine analysis of 1,403 tumor samples. Int J Oncol (2013) 0.89
Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients. Oncol Lett (2010) 0.85
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci (2016) 0.85
A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res (2011) 0.82
Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing. BMC Cancer (2013) 0.80
Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues. J Mol Diagn (2015) 0.79
Emerging treatment options in the management of non-small cell lung cancer. Lung Cancer (Auckl) (2011) 0.78
Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer. Cancer Med (2013) 0.78
Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue. Int J Mol Med (2015) 0.77
Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. Virchows Arch (2016) 0.76
Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. Pharmgenomics Pers Med (2011) 0.75
Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. Virchows Arch (2016) 0.75
EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10). Cancer Manag Res (2016) 0.75
Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests. J Pathol Transl Med (2017) 0.75
[Molecular methods in the diagnosis of sarcoma]. Pathologe (2011) 0.75
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol (2005) 5.07
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol (2009) 3.57
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res (2007) 3.12
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol (2011) 2.44
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res (2011) 2.27
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol (2010) 1.85
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat (2008) 1.64
Mutational profile of GNAQQ209 in human tumors. PLoS One (2009) 1.62
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer (2006) 1.55
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med (2007) 1.52
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest (2007) 1.41
Survivin gene expression in early-stage non-small cell lung cancer. J Pathol (2003) 1.35
microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol (2013) 1.31
Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch (2012) 1.24
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J (2009) 1.23
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer (2009) 1.17
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res (2002) 1.16
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia (2009) 1.15
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res (2012) 1.15
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. J Thorac Oncol (2015) 1.14
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol (2006) 1.11
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arterioscler Thromb Vasc Biol (2005) 1.09
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. Clin Cancer Res (2005) 1.03
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. Cancer Res (2005) 1.03
Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica (2010) 1.00
HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res (2003) 1.00
A unique microRNA signature associated with plaque instability in humans. Stroke (2011) 1.00
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. Hum Mutat (2009) 0.97
Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications. PLoS One (2012) 0.96
Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis. Am J Pathol (2009) 0.96
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. Lab Invest (2002) 0.94
Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. Clin Cancer Res (2004) 0.94
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. Clin Cancer Res (2006) 0.94
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. Int J Biol Markers (2009) 0.93
Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer. J Thorac Oncol (2013) 0.93
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. J Mol Med (Berl) (2012) 0.91
K-ras mutations and cetuximab in colorectal cancer. N Engl J Med (2009) 0.90
Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control. J Clin Endocrinol Metab (2014) 0.90
Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. J Thorac Oncol (2014) 0.89
KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. PLoS One (2011) 0.89
Strategies for improving outcomes in NSCLC: a look to the future. Lung Cancer (2013) 0.88
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. J Thorac Oncol (2015) 0.86
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. J Thorac Oncol (2012) 0.86
Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. Lung Cancer (2004) 0.84
Ligand-dependent activation of EGFR in follicular dendritic cells sarcoma is sustained by local production of cognate ligands. Clin Cancer Res (2013) 0.84
Developing a decision-making model based on an interdisciplinary oncological care group for the management of colorectal cancer. Anticancer Res (2014) 0.83
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. J Clin Oncol (2003) 0.83
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories. Appl Immunohistochem Mol Morphol (2017) 0.82
Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis. Cancer Res (2013) 0.81
High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer. Breast Cancer Res Treat (2009) 0.81
p95HER2 truncated form in resected non-small cell lung cancer. J Thorac Oncol (2012) 0.80
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy. Virchows Arch (2014) 0.79
Relationship between coronary artery disease and C-reactive protein levels in NSTEMI patients with renal dysfunction: a retrospective study. BMC Nephrol (2014) 0.79
Jaagsiekte sheep retrovirus is not detected in human lung adenocarcinomas expressing antigens related to the Gag polyprotein of betaretroviruses. Cancer Lett (2007) 0.78
ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme. J Thorac Oncol (2014) 0.77
Incidence and predictors of postoperative atrial fibrillation in kidney transplant recipients. Transplantation (2013) 0.76
Images in cardiovascular medicine. Membrane-type subaortic stenosis in the adult. Ital Heart J (2003) 0.75
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. J Thorac Oncol (2015) 0.75
PTFE grafts versus tunneled cuffed catheters for hemodialysis: which is the second choice when arteriovenous fistula is not feasible? Artif Organs (2014) 0.75
Fluorescent in situ hybridization as a screening test for HER2 amplification in G2 and G3 breast cancers of lobular and ductal histotype and metastases. Oncol Rep (2008) 0.75